Back to Search
EVANGELIA RAZIS, MD PHD
MD PHD
Medical Oncology Physician
NPI: 1245017656Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
197952(NY)
Research & Publications (20)
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
PMID 19262067·Oncology·2009
3-trial
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.
PMID 18700047·BMC Cancer·2008
8-other
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
PMID 18985033·Br J Cancer·2008
8-other
Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
PMID 17453335·Breast Cancer Res Treat·2008
8-other
Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
PMID 17174087·Eur J Cancer·2007
4-observational
Comparison of HER2 detection methods between central and regional laboratories in Greece.
PMID 18021480·Clin Breast Cancer·2007
4-observational
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
PMID 16720915·Med Oncol·2006
4-observational
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
PMID 16999858·BMC Cancer·2006
8-other
hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients.
PMID 15655560·Br J Cancer·2005
8-other
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
PMID 16148021·Ann Oncol·2005
3-trial
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
PMID 15980985·Breast Cancer Res Treat·2005
3-trial
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
PMID 15746584·Anticancer Drugs·2005
5-case
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
PMID 15655417·Anticancer Drugs·2005
8-other
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
PMID 15581045·Cancer Invest·2004
3-trial
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
PMID 15367413·Ann Oncol·2004
3-trial
Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer.
PMID 15069759·Cancer Invest·2004
3-trial
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
PMID 14758135·Am J Clin Oncol·2004
3-trial
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
PMID 12864940·Clin Breast Cancer·2003
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 362 KIFISSIAS AVE
CHALANDRI, ATTIKI 15233 - Phone
- (693) 240-5390
Quick Facts
- NPI
- 1245017656
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile